Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Daily fosfomycin versus levofloxacin for complicated urinary tract infections.
Rouphael N, Winokur P, Keefer MC, Traenkner J, Drobeniuc A, Doi Y, Munsiff S, Fowler VG, Evans S, Oler RE, Tuyishimire B, Lee M, Ghazaryan V, Chambers HF; DMID 15-0045 study group. Rouphael N, et al. Among authors: chambers hf. mBio. 2023 Oct 31;14(5):e0167723. doi: 10.1128/mbio.01677-23. Epub 2023 Sep 12. mBio. 2023. PMID: 37698412 Free PMC article.
Exploration of a Potential Desirability of Outcome Ranking Endpoint for Complicated Intra-Abdominal Infections Using 9 Registrational Trials for Antibacterial Drugs.
Kinamon T, Gopinath R, Waack U, Needles M, Rubin D, Collyar D, Doernberg SB, Evans S, Hamasaki T, Holland TL, Howard-Anderson J, Chambers H, Fowler VG, Nambiar S, Kim P, Boucher HW. Kinamon T, et al. Clin Infect Dis. 2023 Aug 22;77(4):649-656. doi: 10.1093/cid/ciad239. Clin Infect Dis. 2023. PMID: 37073571 Free PMC article.
Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
Howard-Anderson J, Hamasaki T, Dai W, Collyar D, Rubin D, Nambiar S, Kinamon T, Leister-Tebbe H, Hill C, Geres H, Holland TL, Doernberg SB, Chambers HF, Fowler VG Jr, Evans SR, Boucher HW; Antibacterial Resistance Leadership Group. Howard-Anderson J, et al. Among authors: chambers hf. Clin Infect Dis. 2024 Feb 17;78(2):259-268. doi: 10.1093/cid/ciad576. Clin Infect Dis. 2024. PMID: 37740559
Under the Hood: The Scientific Leadership, Clinical Operations, Statistical and Data Management, and Laboratory Centers of the Antibacterial Resistance Leadership Group.
Cross HR, Greenwood-Quaintance KE, Souli M, Komarow L, Geres HS, Hamasaki T, Chambers HF, Fowler VG, Evans SR, Patel R; Antibacterial Resistance Leadership Group. Cross HR, et al. Among authors: chambers hf. Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S288-S294. doi: 10.1093/cid/ciad529. Clin Infect Dis. 2023. PMID: 37843120
The Future Ain't What It Used to Be…Out With the Old…In With the Better: Antibacterial Resistance Leadership Group Innovations.
Evans SR, Patel R, Hamasaki T, Howard-Anderson J, Kinamon T, King HA, Collyar D, Cross HR, Chambers HF, Fowler VG, Boucher HW; Antibacterial Resistance Leadership Group. Evans SR, et al. Among authors: chambers hf. Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S321-S330. doi: 10.1093/cid/ciad538. Clin Infect Dis. 2023. PMID: 37843122
In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals.
Iovleva A, McElheny CL, Fowler EL, Cober E, Herc ES, Arias CA, Hill C, Baum K, Fowler VG Jr, Chambers HF, Greenwood-Quaintance KE, Patel R, van Duin D, Bonomo RA, Doi Y. Iovleva A, et al. Among authors: chambers hf. Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0125823. doi: 10.1128/aac.01258-23. Epub 2024 Jan 30. Antimicrob Agents Chemother. 2024. PMID: 38289078
Exploration of a Potential DOOR Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs.
Kinamon T, Waack U, Needles M, Rubin D, Collyar D, Doernberg SB, Evans SR, Hamasaki T, Holland TL, Howard-Anderson J, Chambers H, Fowler VG Jr, Nambiar S, Kim P, Boucher HW, Gopinath R. Kinamon T, et al. Clin Infect Dis. 2024 Mar 25:ciae163. doi: 10.1093/cid/ciae163. Online ahead of print. Clin Infect Dis. 2024. PMID: 38527855
Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study.
Reyes J, Komarow L, Chen L, Ge L, Hanson BM, Cober E, Herc E, Alenazi T, Kaye KS, Garcia-Diaz J, Li L, Kanj SS, Liu Z, Oñate JM, Salata RA, Marimuthu K, Gao H, Zong Z, Valderrama-Beltrán SL, Yu Y, Tambyah P, Weston G, Salcedo S, Abbo LM, Xie Q, Ordoñez K, Wang M, Stryjewski ME, Munita JM, Paterson DL, Evans S, Hill C, Baum K, Bonomo RA, Kreiswirth BN, Villegas MV, Patel R, Arias CA, Chambers HF, Fowler VG Jr, Doi Y, van Duin D, Satlin MJ; Antibacterial Resistance Leadership Group and Multi-Drug Resistant Organism Network Investigators. Reyes J, et al. Among authors: chambers hf. Lancet Microbe. 2023 Mar;4(3):e159-e170. doi: 10.1016/S2666-5247(22)00329-9. Epub 2023 Feb 9. Lancet Microbe. 2023. PMID: 36774938 Free PMC article.
International Epidemiology of Carbapenemase-Producing Escherichia coli.
Boutzoukas AE, Komarow L, Chen L, Hanson B, Kanj SS, Liu Z, Salcedo Mendoza S, Ordoñez K, Wang M, Paterson DL, Evans S, Ge L, Giri A, Hill C, Baum K, Bonomo RA, Kreiswirth B, Patel R, Arias CA, Chambers HF, Fowler VG, van Duin D; Multi-Drug Resistant Organism Network Investigators. Boutzoukas AE, et al. Among authors: chambers hf. Clin Infect Dis. 2023 Aug 22;77(4):499-509. doi: 10.1093/cid/ciad288. Clin Infect Dis. 2023. PMID: 37154071 Free PMC article.
258 results